Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Return on Assets (2016 - 2025)

Historic Return on Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to 0.22%.

  • Cartesian Therapeutics' Return on Assets rose 3000.0% to 0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.22%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 0.21% for FY2024, which is 7200.0% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Return on Assets stood at 0.22%, which was up 3000.0% from 0.2% recorded in Q2 2025.
  • Cartesian Therapeutics' Return on Assets' 5-year high stood at 0.15% during Q3 2022, with a 5-year trough of 1.18% in Q4 2023.
  • Its 5-year average for Return on Assets is 0.24%, with a median of 0.2% in 2025.
  • As far as peak fluctuations go, Cartesian Therapeutics' Return on Assets crashed by -13000bps in 2023, and later soared by 10900bps in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Return on Assets stood at 0.08% in 2021, then surged by 248bps to 0.12% in 2022, then tumbled by -1043bps to 1.18% in 2023, then skyrocketed by 93bps to 0.08% in 2024, then crashed by -168bps to 0.22% in 2025.
  • Its Return on Assets stands at 0.22% for Q3 2025, versus 0.2% for Q2 2025 and 0.1% for Q1 2025.